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Abstract
Background: The regional availability of specialized physicians is an important aspect in healthcare of patients with
IBD. The association between physician density and healthcare is not yet clear. Most studies did not consider
district type, which reflects population density. Our research question was, “Do specialist density and district type
influence the healthcare of IBD patients in Germany?”
Methods: We combined a claims dataset from a German health insurance fund with population and physician
data. Four main aspects were investigated: regular specialist visits, drug therapies, surveillance colonoscopy, and
IBD-related hospitalizations. Various regression analyses were performed.
Results: The study cohort was comprised of 21,771 individuals, including 9282 patients with Crohn disease and
12,489 patients with ulcerative colitis. Patients who were living in districts with higher specialist densities were more
likely to attend specialist visits on a regular basis. No difference in the frequencies of TNF-alpha inhibitor therapies
was found. However, individuals from urban areas were more likely to receive a permanent immunosuppressive
therapy with continuous specialist support.
Conclusions: The results revealed that some aspects had positive effects on the probability of implementing healthcare in
accordance with pathways and guidelines. No clear evidence of a general healthcare undersupply in rural areas was found.
Keywords: Inflammatory bowel disease; Quality; Regional differences; Guidelines; Crohn; Ulcerative colitis
JEL classification: I10; I11; I18
Background
Researchers and physicians are constantly searching for
possibilities to improve the healthcare situation of pa-
tients with inflammatory bowel diseases (IBDs). An im-
portant aspect in this discussion is the provision of
healthcare resources, especially the regional availability
of physicians specialized in the treatment of IBD pa-
tients. Principles of optimal healthcare of IBD patients
were defined in the course of the development of
evidence-based, consented IBD pathways and other guide-
lines [1–3]. The consortium (representatives of IBD physi-
cians, patient organizations, and insurers) concluded that
“IBD patients need a comprehensive, easily accessible, and
problem-orientated healthcare” system.
However, whether and how the regional structure, in-
cluding physician density, influences patient healthcare
remain unclear until now. Independent of the indication,
these questions have a high public health and political
impact worldwide because, for example, the small num-
ber of physicians especially in regional areas is often
equated with an undersupply of healthcare.
From an empirical point of view, several studies have
analyzed the impact of physician density on patient
healthcare. Many studies have found a positive association
between physician density and healthcare (e.g., less read-
missions after heart failure [4], or higher cancer survival
[5], or better melanoma prognosis [6]). Others have found
no correlation at all [7, 8] or even negative interrelations
[9]. To our knowledge, only one study concerning IBD
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has been conducted previously [10]. According to the
results, the overall hospitalization rate for IBDs is
similar between residents of high- and those of low-
density counties. However, being a resident in coun-
ties with high physician density is associated with less
complicated disease on hospitalization and lower
hospitalization charges for IBD. Nevertheless, this as-
sociation might also be explained by hospital service
quality, which might be higher in urban counties with
more specialized hospitals.
The IBD study and most of the other aforementioned
studies considered only physician density. The district
type, which reflects, among others, the population dens-
ity and hence the distance within the population, as well
as the distance to physicians, may also have an impact
on healthcare, especially for chronic conditions such as
IBDs. We hypothesized that not only physician density
but also district type has an impact on the healthcare of
patients with Crohn disease (CD) and ulcerative colitis
(UC). Therefore, the overall study question was, “Do
specialist density and district type influence the health-
care of IBD patients in Germany?”
With regard to the study question, it is important to
define healthcare and good healthcare. Here, again, the
IBD pathways [1] and other guidelines provide orienta-
tion. Through our study results, we aimed to scientific-
ally contribute to the discussion of whether patient
healthcare is related to physician density and district
type and provide special insight into the healthcare situ-
ation of IBD patients.
Methods
Data source
To address our study question, we used different datasets.
We combined a claims dataset from a large German statu-
tory health insurance funding organization (Techniker
Krankenkasse [TK], with approximately 7 million insur-
ants in 2008) with population and physician statistical data
[11, 12], with the assumption that this approach could
provide insights into a potential interrelation between
provision quality and regional differences. Claims data are
available for the years 2008–2011. The claims database
provided anonymized information on patient characteris-
tics and detailed data on inpatient and outpatient care
(including diagnoses and operative data), pharmaceuticals,
rehabilitation, remedies and aids as well as sick leave pay-
ments, but no clinical information. All available informa-
tion could be merged via an identification number for
each individual.
Patient selection
The selection of the study population was based on diag-
nostic codes established by the International Classifica-
tion of Diseases, 10th Revision, German Modification
(ICD-10-GM). All the patients who had at least either
CD (ICD-10: K50) or UC diagnosed (ICD-10: K51) in
the inpatient sector or two confirmed diagnoses in the
outpatient sector in 2008 were initially included in the
study. This inclusion criteria have been used before in
many other studies based on German claims data. Con-
sequently, to prevent the inclusion of patients with po-
tentially incident IBDs, the investigation period chosen
was from 2009 to 2011 (hereafter referred to as the
“study period”). Due to data protection regulations,
more recent and extensive data was not available at the
time the analyses were carried out. Patients with an un-
classified IBD type (K52, “other noninfective gastroenter-
itis and colitis”) were excluded.
Patients with no further IBD diagnosis within the
study period were also excluded. Since IBD is a chronic
disease, this approach should exclude individuals with
just a single false diagnosis. Diagnoses of both, CD and
UC in a distinct individual let to exclusion to allow the
definition of mutually exclusive groups. Furthermore, to
be included in the study, patients should be continu-
ously insured in the specific fund plan between 2008
and 2011. Otherwise, no information on e.g. the base-
line period (2008) or on other relevant aspects of this
study (see below) would have been available. A pre-
requisite of the analysis is the assignment of the patients
to an unambiguous district code. Therefore, patients
who changed their place of residence based on official
district codes or had no information on district code in
their records were also excluded.
Study design
Aspects from the IBD treatment pathways were used as
desired reference points to investigate the regional dif-
ferences in healthcare of IBD patients. As mentioned in
the Background section, we investigated three main as-
pects from the treatment pathways as follows: 1) regular
specialist visits, 2) drug therapies, and 3) surveillance
colonoscopy. In addition, we also investigated the pres-
ence of IBD-related hospitalizations.
In the following, we will explain these aspects and clarify
how they were evaluated using the dataset at hand.
1. Regular specialist visits
According to the IBD pathways, IBD patients should
visit a specialist at least once a year [1]. In this case,
gastroenterologists and internists working on an
outpatient basis (with or without more than one key
focus; hereafter referred to as “specialists”) were said
to be specialists (physician identifier nos. 23 and 26)
[1]. Therefore, only patients with at least one
specialist visit in at least every fifth quarter during
the study period were defined as having regular
medical checkups.
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2. Drug therapies
Three different main drug therapies were analyzed.
The selection was based on consented IBD pathways
and other guidelines [1–3] as well as expert
opinions. Prescriptions were identified based on the
anatomical therapeutic chemical (ATC) classification
system.
a. Permanent steroid medication
The following ATC codes were used to classify
steroid medication: A07EA01 and H02AB06,
prednisolone; A07EA03 and H02AB07,
prednisone; and A07EA06, budesonide.
b. Permanent immunosuppressive therapy
The following ATC codes were used for
immunosuppressive therapy: L04AX01,
azathioprine; L01BA01, L04AX03, and M01CX01:
methotrexate; and L01BB02, 6-mercaptopurine.
Steroid dependency or permanent
immunosuppressive therapy was considered if
patients had a relevant prescription in at least
two consecutive quarters during the study period.
c. TNF-α inhibitor therapy
The following ATC code was used for TNF-α
inhibitor therapy: L04AB (etanercept infliximab,
afelimomab, adalimumab, certolizumab pegol,
golimumab (not approved in 2009)). Owing to
the long dosing intervals, patients who had a
respective prescription were considered to have
a TNF-α inhibitor therapy irrespective of the
number of prescriptions.
Regarding drug therapies, two different aspects
were examined. First, we analyzed whether
patients received one of the three aforementioned
drug therapies. For those patients who received
any of the therapies, we additionally analyzed
whether the therapy was implemented in
accordance with the IBD pathways. The pathways
intend that patients who permanently receive one
of the three mentioned drug therapies should
have continuous specialist support [1]. Therefore,
the implementation of the medical therapy is
considered to be “according to the IBD pathways”
if the patient has at least one specialist visit in the
current or following quarter. It should be noted
that in principle, a permanent steroid treatment
under specialist supervision is deemed as the
opposite of good care. However, we could not
verify the choice of therapy with our data.
Therefore, we determined whether the therapy
was implemented under the supervision of a
specialist.
3. Surveillance colonoscopy
Long term UC patients should undergo surveillance
colonoscopy on a regular basis according to the IBD
pathways [1]. The age at initial manifestation of UC
is 15–35 years on average [13]. Following the UC
guidelines [14], regular surveillance colonoscopies
should be performed at the latest after 15 years of
disease duration because of the increased cancer
risk. Because the age at diagnosis was not included
in the dataset, we assumed that UC patients aged
50 years and older should have had at least two
surveillance colonoscopies within the study period
(3 years). Information on whether the patients
underwent surveillance colonoscopies was based on
the German Physicians’ Fee Schedule (EBM)
number in the outpatient sector (EBM: 13421
“surcharge colonoscopy”).
4. IBD-related hospitalizations
We identified all the patients who had at least one
hospitalization with a primary diagnosis of CD (K50)
or UC (K51) and rated with “had an IBD-related
hospitalization.”
We will provide detailed information on the classifica-
tion of district codes and calculation of physician dens-
ities, as they play important roles in the identification of
potential regional differences in the aforementioned
healthcare aspects. The Federal Institute for Research on
Building, Urban Affairs and Spatial Development (BBSR)
classified each district (a total of 412 different districts in
2009; the respective district level codes were included in
the claims data) according to the four different district
types [12]. The differentiation was determined according
to the following settlement structures (including popula-
tion density): 1) autonomous cities, 2) urban areas, 3)
rural areas with concentrations, and 4) rural areas with-
out concentrations. Hence, we linked the district level
code in the claims data, which represents the place of
residence of the respective individual to the respective
BBSR district type.
For each of the aforementioned 412 districts, we calcu-
lated the specialist density and expressed it as the number
of specialists per 10,000 population in each district. Two
different densities were calculated using different out-
patient physician statistical data as follows: 1) outpatient
gastroenterologists + outpatient internist (without more
than one key focus) + inpatient gastroenterologists who
were authorized for outpatient treatment (counted as 0.5,
because half of the time, these physicians were attending
inpatients); 2) outpatient gastroenterologists + outpatient
internists with permission for screening colonoscopy +
inpatient gastroenterologists who were authorized for out-
patient treatment (counted as 0.5). The latter definition
was only used for the analysis of the surveillance colonos-
copy, whereas the former definition was used for all other
analyses. The physician data (their profession and district
code) were compiled based on information from the
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National Association of Statutory Health Insurance
Physicians (KBV) and the Associations of Statutory Health
Insurance Physicians in different federal states.
Statistical analysis
The aforementioned aspects were analyzed using logistic
regression analysis. Therefore, the aspects were dichoto-
mized as described previously. In total, nine different re-
gression analyses were conducted, one for each of the
following aspects: “regular specialist visits,” “surveillance
colonoscopy,” and “IBD-related hospitalization.” With
respect to medication, we conducted two different re-
gression analyses for each aspect. First, we analyzed
whether the prescription of the respective medication is
dependent on regional differences. Second, for the pa-
tients who received such medication, we examined if
they received it in accordance with the IBD pathways. The
dichotomized variables were each used as the dependent
variable in a separate regression model.
Variables for the following items were used as inde-
pendent variables in the models: sex, age at the onset of
the study period (2009), dummy variable accounting for
East and West Germany, specialist density, and district
type. A dummy variable for CD or UC was used, except
for the regression on surveillance colonoscopy. In
addition, we used an interaction term to infer how the
continuous variable “specialist density” affected the re-
spective dependent variable depending on the magnitude
of the categorical variable “district type.” This approach
was used to clarify differences in the impact of specialist
density on the provision of care across different regions.
Coefficients from the logistic regression models were re-
ported as odds ratios. They provide information on how
the odds of, for example, a drug therapy according to
the IBD pathways increase multiplicatively with a single-
unit increase in the independent variable [15]. The odds
ratio is similar to relative risk, particularly if a disease is
rare. Relative risk is the ratio of the risk for occurrence
of a certain event between two groups [16]. Thus, the
relative risk provides information on how much risk has
increased or decreased from an initial level. However,
odds ratio and relative risk are two distinct statistical
concepts and are computed in different ways; discrepan-
cies occur only when the initial risk is high [17].
The odds ratio interpretation of logit coefficients can-
not be used for interaction terms. Unfortunately, the in-
tuition from linear regression models that the marginal
effect of a change in both interacted variables is equal to
the marginal effect of the change in just the interaction
term does not apply to nonlinear models such as logit
models [18]. Both the sign and statistical significance of
such effect can be different across observations. Thus,
the reported odds ratio and z-statistic from the regres-
sion output are not substantive for variables that are
involved in interactions. Therefore, we calculated and
graphed adjusted predictions for these variables. Multi-
collinearity might be an issue in these models. Therefore,
we used the commonly used measures tolerance and
variance inflation factor to test for multicollinearity [19].
Furthermore, we conducted Hosmer and Lemeshow’s
goodness-of-fit test to assess how good the model fits
the data. Given the data source, no ethical approval was
required for the study.
Results
A total of 30,180 individuals were selected for inclusion
based on a relevant diagnosis in the inpatient or out-
patient sector. The final study cohort was comprised of
21,771 individuals, including 9282 CD and 12,489 UC pa-
tients (Fig. 1). The mean age of the cohort was approxi-
mately 50 years and the sex distribution was nearly equal
with females comprising 49 % of the cohort. Almost 80 %
lived in urban areas or autonomous cities. Further details
of the cohort are given in Additional file 1.
In the following, the results of each main aspect are
reported separately:
1. Regular specialist visits
Of all the IBD patients, 21 % (4589) had a regular
specialist visit during the study period, including
1855 and 2734 patients from the CD and UC
cohorts, respectively (Table 1). The predicted
probabilities (Fig. 2) revealed that the patients who
were living in areas with higher specialist density
were more likely to have specialist visits on a regular
basis. This relationship is clearer in both urban
district types. However, no relationship was
observed in the rural areas with concentrations.
2. Drug therapies
Three different main drug therapies were analyzed.
Of the study population, 22 % (4708), 16 % (3434),
and 4 % (900) received a permanent steroid
medication, permanent immunosuppressive therapy,
and TNF-α inhibitor therapy, respectively. The
probability of receiving one of the three drug
therapies hardly changed, subject to specialist
density and district types. Table 1 shows that the
proportion of patients who received such drug
therapies in combination with regular specialist visits
was highest for the TNF-α inhibitor therapy. The
plot of the predicted probabilities (Fig. 3) revealed
that the probability of receiving a permanent steroid
medication or immunosuppressive therapy in
combination with regular specialist visits was
significantly positively associated with specialist
density. Furthermore, this relationship was strongest
in the urban district types. However, Fig. 3 shows
that the probability of receiving a TNF-α inhibitor
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therapy in combination with regular specialist visits
took a highly different course. As a result, the
probability increased and decreased with the higher
specialist density in the rural and urban areas,
respectively. However, this model is statistically not
significant in contrast to all the other regression
models in the present study.
3. Surveillance colonoscopy
The group of UC patients, who were 50 years and
older, comprised of 6664 individuals. Of the patients,
9 % (587) had regular surveillance colonoscopies
during the study period (Table 1). Figure 4 shows
that the probability of undergoing regular
colonoscopy was mainly independent of the
specialist density in the rural areas, whereas in the
urban areas, the probability of undergoing regular
colonoscopy clearly increased with specialist density.
The variation is particularly obvious in autonomous
cities, where the probability of undergoing regular
colonoscopy increased from 10 % for a specialist
density of 0.4 per 10,000 inhabitants to 40 % for a
specialist density of 1.4 per 10,000 inhabitants.
4. IBD-related hospitalizations
The presence of an IBD-related hospitalization is a
surrogate marker of a complicated disease course
and is therefore often used as a secondary end point
Fig. 1 Patient selection flowchart
Table 1 Descriptive results (main aspects)
Crohn Disease (CD) Ulcerative Colitis (UC) Total
n = 9282 n = 12,489 n = 21,771
Regular specialist visits 20 % 22 % 21 %
Medication
Permanent steroid therapy Received medication 28 % 17 % 22 %
With continuous specialist supporta 32 % 37 % 34 %
Permanent immunosuppressive therapy Received medication 22 % 11 % 16 %
With continuous specialist supporta 34 % 38 % 36 %
TNF-α inhibitors therapy Received medication 7 % 2 % 4 %
With continuous specialist supporta 50 % 51 % 50 %
Surveillance colonoscopy (UC patients aged≥ 50 years (n = 6664)) / 9 % /
IBD-related hospitalization 13 % 5 % 9 %
aOnly patients who received the relevant medication were considered
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in clinical trials. Approximately 9 % of all the IBD
patients had at least one IBD-related hospitalization
within the study period (Table 1). Moreover, the
probability of having an IBD-related hospitalization
was significantly influenced neither by the specialist
density nor by the various district types.
Aside from the main results with regard to specialist
density and district types, we analyzed the impact of
age, sex, and IBD type (CD or UC) on the aspects of
interest using the regression results. These results
are provided in Additional file 1.
Discussion
To our knowledge, this is the first study to analyze the
impact of specialist density and district type on the
healthcare of IBD patients. The following four main re-
sults were derived:
1) The probability of attending regular specialist visits
increased with specialist density and was more likely
for individuals who were living in urban areas than
in those who were living in rural areas. One can
hypothesize that this result is related to the fact that
a higher specialist density may facilitate the access of
patients to these specialists. The slight increase
illustrated in Fig. 2 clarifies that this might also
apply to rural districts. Furthermore, the higher
likelihood for urban areas was probably due to the
fact that the patient-to-physician distance is shorter
than in the rural areas. Therefore, patients visit their
physicians more regularly. Our result concurs with
that of Busato et al. [20], who analyzed the per
capita consultation rates with primary care
physicians in Switzerland. They found that the
regional density of physicians in independent
practice was also significantly associated with
annual consultation rates and indicated an associated
increase of 0.10 for each additional primary care
physician in a population of 10,000 inhabitants.
2) The probability of receiving certain IBD drugs was
regardless of regional differences. Our results did
not indicate general differences in prescription
behavior, contrary to the results from the study by
Bohlken et al. [8], who examined regional variability
in antidementia drug prescriptions in metropolitan
and rural regions of Germany. They suggested that
the drug coverage was better in rural than in urban
areas despite the lower physician density.
Furthermore, Windt et al. [21] examined the
relationship between prescriptions of TNF-α inhibitors
and regional differences based on prescription claims
data in 2010. They revealed that the average revenue
per insured person was often higher in districts
of East Germany. We found no evidence of a higher
probability of receiving a TNF-α inhibitor therapy in
East Germany. However, we do not focus on the
number of prescriptions and the related revenues and
the results are not fully comparable.
Fig. 2 Probability of attending regular specialist visits
Lange et al. Health Economics Review  (2015) 5:29 Page 6 of 11
However, our results revealed that the individuals who
were living in urban areas were more likely to receive a
permanent immunosuppressive therapy in combination
with regular specialist visits. A higher specialist density
also had a positive impact on the probability. The path-
ways define that patients who receive one of the afore-
mentioned drug therapies should have continuous
specialist support. Therefore, again, this result could be
related to the patients’ easier access to specialists with
the increasing specialist density and shorter distances in
the urban areas. It is interesting that this insight is not
true for TNF-α inhibitor therapies and the probability of
receiving such therapies in combination with regular
specialist visits diminished with the increasing specialist
density in the urban areas. One reason for this discrep-
ancy could be that in the urban areas with higher spe-
cialist density, many other internists treated IBD
patients, their threshold to prescribe azathioprine or
methotrexate presumably being lower that for anti-TNF.
Thus, the observed probability of a pathway-consistent
anti-TNF therapy decreased.
3) The probability of undergoing regular surveillance
colonoscopies increased with specialist density. This
insight, however, only applies to urban areas. Again,
we assume that the higher density facilitated the
patients’ access to specialists, particularly in the
urban areas. Moreover, in Germany, most
surveillance colonoscopies are remunerated from
non-budget funds and physicians earn extra money.
This fact suggests that our result was likely caused
by a supply-induced demand, which is said to be
stronger in areas with higher physician density
[22–24]. Furthermore, physicians’ time resources
might have been scarcer in the rural than in the
urban areas [25]. It is noteworthy that only 9 %
underwent surveillance colonoscopy on a regular
basis. However, this result is in concordance with
the result from the study by Kaltz et al. [26]. They
revealed that biopsy during colonoscopy that
conformed with the guidelines was performed only
in 9 % of cases in a colorectal cancer risk group of
UC patients in Germany. In addition, other studies
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have shown that the adherence to surveillance
colonoscopy is poor in IBD patients [27–29]. As a
sensitivity analysis, the probability of undergoing
regular surveillance colonoscopies was analyzed in
relation to age. No significant differences were found
between the various age classes.
4) The probability of having an IBD-related
hospitalization was independent of the specialist
density and district type. Our result did not indicate
general differences in care, in agreement with the
results from the study by Ananthakrishnan et al.
[10]. They examined whether the availability of
physicians is an important determinant of IBD
hospitalization in different US counties and found
that the overall rate of IBD hospitalizations was
similar between residents of high- and those of
low-density counties. However, complications were
encountered more commonly among hospitalized
patients in counties with low physician density.
Other authors have shown that higher physician dens-
ity may be associated with an increase in healthcare
utilization and costs [30]. With regard to the probability
of having at least one IBD hospitalization, our results
suggest that this does not appear to be the case for IBD.
Moreover, factors other than specialist availability may
influence the need for hospitalization in IBD patients. In
addition, specialist density is merely one marker of avail-
ability of regular care. Finally, the effect of specialist
density on the probability of having a hospitalization
may be small, with other factors playing a more domin-
ant role [10].
Further discussion points related to the results of the
impact of age, sex, and IBD-type are provided in
Additional file 1.
Our results show that specialist density and district type
both have an impact on the healthcare of IBD patients.
However, our analyses were mainly based on the German
IBD pathways that were formulated as a minimum degree
of care for IBD patients. They did not compile data on
healthcare oversupply. Therefore, our analyses intend to
determine healthcare undersupply only. To summarize,
our data do not provide any clear evidence of a general
healthcare undersupply (defined by the pathways) for IBD
patients in rural areas. However, they reveal that in gen-
eral, a significantly large proportion of patients are not
treated according to the IBD pathways. Particularly, the
compliance in terms of regular specialist visits and surveil-
lance colonoscopy is very low. Therefore, patients and
providers should be encouraged to improve care. How-
ever, against this background, the question of whether the
pathways are actually suitable for a comprehensive imple-
mentation needs to be answered. If this is not the case,
guidelines and pathways should be adapted in a practical
and realistic way. Further research is necessary to clarify
the impact of differences in quality and quantity of certain
treatments on, for example, healthcare cost and quality of
life of IBD patients.
Furthermore, we would like to clarify that “adequate”
healthcare of IBD patients is not solely related to the
Fig. 4 Probability of undergoing regular surveillance colonoscopies
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frequency of specialist visits. To examine the impact of
increased utilization, it would be interesting to link our
insights to other utility measures and clinical data, such
as quality of life, health status, and well-being of pa-
tients. These data are not available in German claims
data. Therefore, our study is a first approach to assess
the healthcare provided for IBD patients. The German
IBD pathways offer more recommendations regarding
other aspects that, however, cannot be analyzed by using
claims data. Nevertheless, the IBD pathways were devel-
oped in interdisciplinary working groups, including pa-
tient representatives, and should represent a consensus
on the optimal treatment of IBD patients [1].
In the following, we will highlight study limitations
with respect to the variables used, the methodology, and
the generalizability of the results, even though the data
and methodology that we used were the best available to
our knowledge. German claims data have some general
limitations that are not further discussed here [31]. Con-
cerning the independent variables, we emphasize that we
could not obtain any variable that comprises clinical data
(e.g. disease activity, severity grade of a disease, symptom
scores, laboratory test results, quality-of-life data,
smoking status, and body mass index) owing to data
protection regulations. Therefore, a classification regard-
ing disease severity was only possible based on drug pre-
scriptions. There might be other differences between our
patients that could have biased our results.
The district type variable was also subject to limita-
tions. As stated in the Methods section, the variable re-
flects, among others, population density and was set by
the government. However, it does not necessarily reflect
the distances to large cities, and patients living in areas
next to large cities might need to travel to visit special-
ists. If that is the case, our results might have been
biased by the small differences between urban and rural
areas. Another important variable in our study was spe-
cialist density, which accounted for gastroenterologists,
internists (without a key focus), and gastroenterological
authorized physicians. This definition was subject to un-
certainty because it could not precisely foresee which
physician was considered as an IBD specialist. Therefore,
we conducted our analyses with an alternative definition,
taking into account only gastroenterologists and gastro-
enterological authorized physicians. Our results were
changed slightly, but the interpretation remained the
same. Thus, we consider our results robust regarding
this aspect.
Concerning our dependent variables, we want to high-
light that the analysis on regular specialist visits was lim-
ited by the nature of the German claims data and
reimbursement schemes in the inpatient sector. Services
in the inpatient sector are reimbursed based on Diagno-
sis Related Groups, and data do not comprise the
information on whether patients were treated by an IBD
specialist or not. Therefore, specialist visits in the in-
patient sector were not considered in the present study,
and some patients who probably had regular specialist
visits might have been coded as not attending regular
specialist visits. However, under the assumption that the
prevalence of specialist visits in the inpatient sector is
similar in urban and rural areas, this problem applies to
all patients, and therefore should not bias our results in
relative terms.
Furthermore, our definition of a steroid medication
might have biased our results. Only prednisolone, pred-
nisone, and budesonide were considered. Although these
drugs are the most commonly used in the treatment of
IBD, other steroids might have been used as substitutes
[32]. In addition, that fact that drug prescriptions are
motivated by diseases other than IBD cannot be ruled
out. This is especially the case with TNF-α inhibitors,
which are also used for other diseases such as rheumatic
diseases. This fact might have biased our analysis of drug
treatments. Finally, the need for surveillance colonos-
copies was closely associated with disease severity. How-
ever, information on severity was not available in our
data. Patients with extensive disease have an increased
risk for developing dysplasia and colorectal cancer and
thus should have regular colonoscopies. Patient with only
proctitis or proctosigmoiditis do not have an increased
risk. Therefore, our results regarding colonoscopies might
have been biased owing to the lack of such data.
Our methodological approach also had limitations that
need to be considered. We emphasize that the odds ratio
interpretation, which is used in the present study, is not
equivalent to the relative risk interpretation. Therefore,
for example, an odds ratio of 2 does not necessarily
correspond to a twofold increase in the risk for a certain
exposure. This interpretation would be correct for a
relative risk of 2. However, both measures are quite simi-
lar under certain conditions, and differences do not lead
to a different interpretation in the present study. Fur-
thermore, we included age as a simple linear specifica-
tion in our models only. This approach may not be
appropriate to reveal the effect of age on the outcomes.
However, we repeated our analyses to include a squared
age term, but our results were unchanged.
Finally, we highlight that the generalizability of our re-
sults to all IBD patients in Germany is limited, although
the TK is one of the largest sickness funding organization
in Germany. This is mainly due to the fact that each sick-
ness fund differs in terms of the group of insured individ-
uals. The comparison of our data with those for the total
population of Germany demonstrated that in our data, the
individuals who were living in the urban areas and old
states of Germany were slightly overrepresented. There-
fore, a generalization should be applied with caution.
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However, no information was available on the geograph-
ical distribution of the IBD patients in Germany. More-
over, the estimated number of unreported IBD cases can
be assumed to be high in Germany owing to the fact that
the disease often progresses over a long period [33]. If
these cases are not evenly distributed across the urban and
rural areas, our results could be biased. Lastly, it remains
unclear the extent to which our results are due to im-
proved health care accessibility or supply-induced demand.
This issue merit further research attention to explore the
possibilities to improve health care in IBD patients.
Conclusions
The evidence from this study suggests that factors such
as specialist density and district type determine the
healthcare provided to IBD patients in terms of certain
recommendations from the pathways. However, no clear
evidence of a general healthcare undersupply for IBD pa-
tients in rural areas was found. Furthermore, age, sex,
and IBD type are also important determinants. Finally,
the analyses support the application and modification
process of the IBD pathways, which should be drawn up
in a practical and realistic way.
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